The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development.

Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. Title: HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in preclinical solid tumor models Title: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker-selected preclinical models of squamous cell carcinomas Session Date and Time: Monday 1:30 PM - 5:00 PM ET Session Category: Experimental and Molecular Therapeutics We look forward to discussing the promising data for our novel HER3-targeting therapeutics with the oncology research community at AACR.' 'The potent anti-tumor activity we see from our clinical-stage HMBD-001 program is exciting and represents a broad treatment opportunity due to conserved sensitivity to HER3 and EGFR inhibition across multiple squamous carcinomas. At AACR, we will have the first publication of preclinical results for our potentially best-in-class HER3 ADC,' said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience. 'We are excited to be on the cusp of the new horizon of therapies for HER3-expressing cancers.

The HMBD-501 poster discusses the rational design of the HER3 ADC, its potentially best-in-class safety and tolerability profiles, and superior inhibition of tumor growth compared to other HER3 ADCs, across a range of preclinical cancer models. Robust tumor growth inhibition in various preclinical squamous cancer models, including lung, esophageal and head and neck, is observed with HMBD-001 when used as monotherapy and in combination with cetuximab. The poster for HMBD-001 highlights that inhibition of HER3 has broad applicability in squamous cell carcinomas and this anti-tumor activity can be enhanced with concurrent inhibition of EGFR, with significant potential to improve patient outcomes.

The company will present a poster describing the efficacy of HMBD-001, a clinical-stage anti-HER3 mAb currently in Phase 1a clinical trial ( NCT05057013), across multiple preclinical models of squamous cell carcinomas and a poster demonstrating the efficacy and tolerability of HMBD-501, a next generation HER3-targeting antibody-drug conjugate (ADC), in preclinical solid tumor models.

Affinity designer class